Q4-2024 Report
The first year after the strategic review and focus on capital efficiency and profitability. More than 17,000 packages of medicines (medicinal cannabis) sold in Denmark in 2024.
Released 17 February 2025.
Q4-2024 Report
The first year after the strategic review and focus on capital efficiency and profitability. More than 17,000 packages of medicines (medicinal cannabis) sold in Denmark in 2024.
Released 17 February 2025.
Right now
Latest Announcements
Please visit the press room, your go-to destination for the latest updates and announcements. Here, you will find all the recent news, press releases, and important information about activities and updates.
DanCann Pharma sold +17,000 packages of medicine in 2024.
In 2024, DanCann Pharma sold more than 17,000 packages of medicine to Danish pharmacies. The ambition is to exceed 20,000 packages of medicine in 2025.
Financial Numbers
Calendar and Events (2025)
Annual Report 2024: March 31, 2025 (PM 06:00 CET)
Annual General Meeting: April 14, 2025 (AM 09:00 CET)
Q1 2025 Report: April 28, 2025 (PM 06:00 CET)
Q2 2025 Report: August 25, 2025 (PM 06:00 CET)
Q3 2025 Report: October 27, 2025 (PM 06:00 CET)
No employees
Corporate Governance
DanCann Pharma is a Danish public limited company governed by Danish legislation, mainly the Danish Companies Act and the Danish Annual Accounts Act.
Following the listing of the company’s shares on Spotlight Stock Market, the company will apply and adhere to Spotlight Stock Markets’ rules and regulations.
DanCann Pharma's law firm is Mazanti-Andersen.
DanCann Pharma’s auditor is Deloitte, Denmark.
Invest in DanCann Pharma
DanCann Pharma was listed in November 2020 on the Spotlight Stock Market. DanCann Pharma is traded with the ticker name "DANCAN".
Invest in DanCann Pharma
DanCann Pharma was listed in November 2020 on the Spotlight Stock Market. DanCann Pharma is traded with the ticker name "DANCAN".
Would you like to know more?
Please do not hesitate to reach out to us. Connect with our team today and discover the many ways we can collaborate. Contact us now to get started.